Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
- PMID: 1329440
- DOI: 10.1002/jbmr.5650070909
Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
Abstract
This is a retrospective study of 15 postmenopausal or amenorrheic women aged 34-78 years who had taken prednisone for 6-108 months and were followed for 1 year while continuing to take doses of 5-15 mg/day. A total of 8 patients were treated with 0.6256 mg Premarin daily for 25 days and 5 mg/day of medroxyprogesterone on days 15-25 (ERT, group 2); 7 were followed without ERT (group 1). A group of 17 women, matched for age, were randomly selected from our computerized data base to serve as a control group (group 3), and 10 women of similar age who were taking ERT only (group 4) were selected to compare the response to ERT to that of group 2. Bone density (BD) was measured in the lumbar spine baseline and at 1 year using dual-photon or dual-energy x-ray absorptiometry. Spine density did not change significantly during the year of observation in group 1. Although BD decreased in 5 of 7 patients, the change was not significant (-0.034 +/- 0.018 g/cm2, p = 0.10). In group 2 BD increased significantly, with 7 of 8 patients showing an increase (0.037 +/- 0.011 g/cm2, p = 0.008). BD did not change significantly in the control group (0.013 +/- 0.008 g/cm2, p = 0.16). Loss of bone from the spine was significantly greater in group 1 than in controls (p = 0.02), but changes in group 2 were similar to those in the control group (p = 0.66).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
[Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].Zhonghua Fu Chan Ke Za Zhi. 2002 May;37(5):267-70. Zhonghua Fu Chan Ke Za Zhi. 2002. PMID: 12133397 Clinical Trial. Chinese.
-
Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.Arch Gynecol Obstet. 2003 Jun;268(2):105-6. doi: 10.1007/s00404-002-0340-5. Epub 2002 Aug 17. Arch Gynecol Obstet. 2003. PMID: 12768299
-
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.Am J Obstet Gynecol. 2001 Nov;185(5):1180-5. doi: 10.1067/mob.2001.117669. Am J Obstet Gynecol. 2001. PMID: 11717654 Clinical Trial.
-
Quantitative assessment of bone mineral density during estrogen replacement therapy.Gynecol Endocrinol. 1999 Dec;13 Suppl 6:29-34. Gynecol Endocrinol. 1999. PMID: 10862266 Review. No abstract available.
-
Monitoring skeletal response to estrogen.Am J Obstet Gynecol. 1989 Oct;161(4):843-8. doi: 10.1016/0002-9378(89)90732-1. Am J Obstet Gynecol. 1989. PMID: 2679103 Review.
Cited by
-
Prevention of glucocorticoid induced osteoporosis.Ann Rheum Dis. 1997 Sep;56(9):507-9. doi: 10.1136/ard.56.9.507. Ann Rheum Dis. 1997. PMID: 9370871 Free PMC article. No abstract available.
-
Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men.Ann Rheum Dis. 2000 Apr;59(4):269-75. doi: 10.1136/ard.59.4.269. Ann Rheum Dis. 2000. PMID: 10733473 Free PMC article.
-
Basic and clinical aspects of osteoporosis in inflammatory bowel disease.World J Gastroenterol. 2007 Dec 14;13(46):6156-65. doi: 10.3748/wjg.v13.i46.6156. World J Gastroenterol. 2007. PMID: 18069754 Free PMC article. Review.
-
Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.Arthritis Res Ther. 2011 Jun 20;13(3):R96. doi: 10.1186/ar3371. Arthritis Res Ther. 2011. PMID: 21689408 Free PMC article.
-
Management of bone disease in patients on long term glucocorticoid therapy.Gut. 1999 Jun;44(6):770-2. doi: 10.1136/gut.44.6.770. Gut. 1999. PMID: 10323872 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical